Antitrust Battle Ignites as Pfizer Obstructs Novo's $9 Billion Metsera Acquisition

Bitget App

Trade smarter

Bitget

News

Markets

Antitrust Battle Ignites as Pfizer Obstructs Novo's $9 Billion Metsera Acquisition

Bitget-RWA2025/11/06 08:30

By:Bitget-RWA

- Novo Nordisk's $9B Metsera acquisition faces Pfizer lawsuits alleging antitrust violations and breach of contract under U.S. antitrust laws. - Pfizer claims the deal delays GLP-1 competition and binds Metsera to restrictive covenants, while Novo dismisses allegations as "baseless" and confident in antitrust compliance. - Novo cuts $8B annual costs, launches Wegovy pill, and partners with Costco/Walmart to counter 9% market share loss amid U.S. pricing pressures and patent expirations. - The obesity drug

Novo Nordisk, the Danish pharmaceutical leader known for its best-selling weight-loss medications Wegovy and Ozempic, is facing a twofold challenge as it works to maintain its top position amid ongoing lawsuits and updated financial projections. The company’s planned $9 billion purchase of biotech company

Metsera

has come under heavy examination, with

Pfizer

initiating two legal actions that accuse Novo of anti-competitive behavior and violating contractual agreements, according to a

PharmExec article

. These lawsuits, which cite the Sherman and Clayton Acts, seek to prevent Novo’s acquisition and to uphold Pfizer’s initial $7.3 billion bid for Metsera, as detailed by

Seeking Alpha

Pfizer contends that

Novo

Nordisk’s deal structure is intended to postpone Metsera’s participation in the GLP-1 drug market, thereby limiting competition and safeguarding Novo’s market dominance, according to a

Yahoo News story

. The complaint alleges that Novo’s upfront payment of $6.5 billion to Metsera—prior to regulatory clearance—binds Metsera to restrictive terms that could impede its research and development. Novo, on the other hand, has called these accusations “without merit,” maintaining that it has followed the Pfizer merger agreement and is confident the deal meets antitrust standards, as reported by

Global Banking & Finance

. Metsera’s board has also dismissed Pfizer’s arguments, claiming Pfizer is trying to “use litigation to force a lower purchase price.”

This legal dispute highlights the enormous stakes in the obesity medication industry, where experts predict annual sales could climb to $150 billion in the near future. Novo’s intended acquisition of Metsera would strengthen its development pipeline with new therapies that could bring in $5 billion in revenue. At the same time, Pfizer’s strategy to enter this market depends on securing Metsera to advance its own weight-loss drugs, a key move as it faces patent losses and shrinking income from older medicines.

On the financial front,

Novo Nordisk

posted robust third-quarter numbers, with sales rising 15% and operating profit up 10% for the first nine months of 2025, according to its

Q3 2025 earnings highlights

. Still, the company has lowered its full-year outlook, citing stronger competition and mounting pricing challenges. It now anticipates sales growth of 8–11% (at constant exchange rates) and operating profit growth of 4–7%, a reduction from earlier estimates, as noted in a

BioSpace press release

. These changes reflect difficulties in the U.S. market, where compounded GLP-1 drugs and regulatory obstacles, such as price controls from the Inflation Reduction Act, are putting pressure on profits, according to

GuruFocus

To address these challenges, Novo is implementing an $8 billion annual cost-saving plan and reducing its global workforce by 9,000, as highlighted in its Q3 2025 earnings report. The company also revealed new product launches, including an oral version of Wegovy, and has formed partnerships with major retailers Costco and Walmart to broaden its market reach, according to an

earnings call transcript

. These initiatives are designed to recover from a 9% decline in Novo’s market share in the diabetes and obesity space over the past year, the company stated in its earnings call.

As the legal contest over Metsera continues, Novo Nordisk’s success will depend on how well it manages legal risks while driving innovation to stay ahead in this fast-changing industry.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

- Mastercard explores $1.5B-$2B acquisition of MiCAR-licensed crypto infrastructure firm Zerohash to expand Web3 capabilities. - Partners with Ripple to pilot RLUSD stablecoin for credit card settlements on XRP Ledger, enabling instant cross-border transactions. - Zerohash's regulatory compliance and $1B valuation align with Mastercard's strategy to bridge traditional finance and blockchain infrastructure. - RLUSD's NYDFS-backed growth and XRP Ledger integration could reshape global payments while reinforc

Bitget-RWA•2025/11/06 12:50

DoorDash Shares Drop 10% as Focus on Growth Reinvestment Outweighs Earnings Outperformance

- DoorDash's stock fell over 10% post-earnings despite $3.45B revenue beat, driven by 25% GOV growth and 21% order increase. - Management signaled $300M+ 2026 AI/tool investments and revised Deliveroo's EBITDA contribution down by $32-40M due to accounting changes. - Analysts cut price targets (Wells Fargo to $239) as $754M adjusted EBITDA (up 41%) was overshadowed by reinvestment concerns despite $723M free cash flow. - 42% YTD gains amplified sell-off sensitivity, with 31 analysts retaining "Moderate Buy

Bitget-RWA•2025/11/06 12:50

DoorDash Shares Drop 10% as Focus on Growth Reinvestment Outweighs Earnings Outperformance

Savers Confront a Choice: Lock in Safe 5% Returns or Chase DeFi's Tempting 12%

- Fed rate cuts in 2025 spurred high-yield savings accounts offering up to 5.00% APY, outpacing traditional banks' 0.40% average. - DeFi platforms like ZEROBASE and Maple Finance offer 12-7% APY on stablecoins, but require higher risk tolerance and short liquidity periods. - Banks may reduce APYs if further Fed cuts occur, while FDIC-insured high-yield accounts remain popular for inflation protection. - Alternative assets like Bitcoin and dividend stocks (e.g., Viper Energy's 3.49% yield) show growing comp

Bitget-RWA•2025/11/06 12:28

Savers Confront a Choice: Lock in Safe 5% Returns or Chase DeFi's Tempting 12%

Bitcoin News Update: Institutions Remain Wary as Retail Investors Drive Crypto Innovation—The Battle for Dominance Escalates

- Bitcoin fluctuates near $110,000 amid ETF outflows and revised institutional price targets, with long-term holders creating resistance through strategic BTC distributions. - Ethereum and XRP show resilience with ETF inflows and whale activity, while emerging projects like Remittix ($27.8M raised) and Noomez gain traction through innovative tokenomics. - Analysts remain divided: some see $120,000 potential if Bitcoin breaks key averages, while others warn of $72,000 corrections amid macroeconomic uncertai

Bitget-RWA•2025/11/06 12:14